Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Shares of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) are trending higher Wednesday following positive comments from FBR Capital.
Andrew Berens maintained an Outperform rating and $12 price target.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Berens noted that Achillion’s NS5a inhibitor is considered to be the best in class.
Berens commented on the abstracts released by the company Wednesday stating, "We view this data as incrementally positive, as it shows ACHN’s NS5A appears to have potent activity when used in combination with a nuc backbone. This is important ahead of phase I proof-of-concept data for Achillion’s main value driver, the nucleotide polymerase inhibitor (nuc) ACH-3422, due in late fall 2014."
Berens finds that the data adds value to Achillion’s NS5A/nuc combination, making it an ideal takeover candidate.
Shares of Achillion Pharmaceuticals recently traded at $10.59, up 8.6 percent.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.